IDH1- and IDH2-mutated acute myeloid leukaemia

What changed: IDH1- and IDH2-mutated acute myeloid leukaemia

Every dated change on the records linked to IDH1- and IDH2-mutated acute myeloid leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval5Trial result2Milestone4This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordIDH1- and IDH2-mutated acute myeloid leukaemia
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 4

2020 · 1

2020Trial resultVIALE-A
VIALE-A reported
OS 14.

2019 · 1

2019ApprovalIvosidenib
Ivosidenib approved in US
Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy

2018 · 2

2017 · 2

2009 · 1

2009MilestoneIDH1 / IDH2
IDH1 mutations found in AML after their discovery in glioma
A milestone in how this cancer is treated.